share_log

6-K: Report of foreign private issuer (related to financial reporting)

6-K: Report of foreign private issuer (related to financial reporting)

6-K：外國發行人報告（業績相關）
美股SEC公告 ·  11/06 19:37

牛牛AI助理已提取核心訊息

Novo Nordisk A/S, a leading global healthcare company, reported a significant increase in sales and operating profit for the first nine months of 2024. Sales rose by 23% in Danish kroner and 24% at constant exchange rates (CER) to DKK 204.7 billion, while operating profit grew by 21% in Danish kroner and 22% at CER to DKK 91.6 billion. The growth was primarily driven by the Diabetes and Obesity care segment, with GLP-1 diabetes sales increasing by 25% in Danish kroner and Obesity care growing by 44% to DKK 43.7 billion. North America Operations saw a 31% increase in sales, with the US market contributing significantly to this growth. The company also completed several clinical trials, including the phase 2a trial with monlunabant in obesity, and announced positive results from the...Show More
Novo Nordisk A/S, a leading global healthcare company, reported a significant increase in sales and operating profit for the first nine months of 2024. Sales rose by 23% in Danish kroner and 24% at constant exchange rates (CER) to DKK 204.7 billion, while operating profit grew by 21% in Danish kroner and 22% at CER to DKK 91.6 billion. The growth was primarily driven by the Diabetes and Obesity care segment, with GLP-1 diabetes sales increasing by 25% in Danish kroner and Obesity care growing by 44% to DKK 43.7 billion. North America Operations saw a 31% increase in sales, with the US market contributing significantly to this growth. The company also completed several clinical trials, including the phase 2a trial with monlunabant in obesity, and announced positive results from the SOUL cardiovascular outcomes trial with oral semaglutide. Novo Nordisk expects to initiate a phase 2b trial in obesity in 2025. For the full year 2024, Novo Nordisk now expects sales growth to be between 23-27% at CER and operating profit growth to be between 21-27% at CER. The company's CEO, Lars Fruergaard Jørgensen, expressed satisfaction with the performance and highlighted the increasing demand for GLP-1-based diabetes and obesity treatments. An earnings call was held on November 6, 2024, to discuss these results.
諾和諾德是全球領先的醫療保健公司，在2024年前九個月報告銷售額和營業利潤顯著增長。銷售額以丹麥克朗計算增長了23%，以恒定匯率計算增長了24%，達到2047億丹麥克朗，而營業利潤以丹麥克朗計算增長了21%，以恒定匯率計算增長了22%，達到916億丹麥克朗。增長主要由糖尿病和肥胖護理領域推動，GLP-1糖尿病銷售額以丹麥克朗計算增長了25%，肥胖護理增長了44%，達到437億丹麥克朗。北美業務銷售額增長31%，美國市場對此增長做出了重要貢獻。公司還完成了幾項臨床試驗，包括在肥胖症中進行的2a期蒙盧那班試驗，並宣佈口服賽馬格列汀在SOUL心血管結局試驗中取得積極結果。諾和諾德預計將在2025年開...展開全部
諾和諾德是全球領先的醫療保健公司，在2024年前九個月報告銷售額和營業利潤顯著增長。銷售額以丹麥克朗計算增長了23%，以恒定匯率計算增長了24%，達到2047億丹麥克朗，而營業利潤以丹麥克朗計算增長了21%，以恒定匯率計算增長了22%，達到916億丹麥克朗。增長主要由糖尿病和肥胖護理領域推動，GLP-1糖尿病銷售額以丹麥克朗計算增長了25%，肥胖護理增長了44%，達到437億丹麥克朗。北美業務銷售額增長31%，美國市場對此增長做出了重要貢獻。公司還完成了幾項臨床試驗，包括在肥胖症中進行的2a期蒙盧那班試驗，並宣佈口服賽馬格列汀在SOUL心血管結局試驗中取得積極結果。諾和諾德預計將在2025年開展20億肥胖症試驗。至2024年全年，諾和諾德現在預計銷售增長率將在23-27%的匯率區間內，營業利潤增長率將在21-27%的匯率區間內。公司首席執行官拉斯·弗呂加德·約根森對業績表示滿意，並強調對GLP-1類糖尿病和肥胖治療需求增加的重點。於2024年11月6日舉行了一場業績會，討論這些結果。

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間